Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation

1.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F, Global Cancer Statistics 2020. : GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries, CA: a cancer journal for clinicians, 71 (2021) 209–49https://doi.org/10.3322/caac.21660.

2.

Li S, Wang A, Wu Y, He S, Shuai W, Zhao M, Wang G, et al. Targeted therapy for non-small-cell lung cancer: new insights into regulated cell death combined with immunotherapy. Immunol Rev. 2023. https://doi.org/10.1111/imr.13274.CrossRefPubMed

3.

Yang L, Dou Y, Sui Z, Cheng H, Liu X, Wang Q, Xu M, et al. Upregulated miRNA-182-5p expression in tumor tissue and peripheral blood samples from patients with non-small cell lung cancer is associated with downregulated caspase 2 expression. Experimental Therapeutic Med. 2020;19:603–10. https://doi.org/10.3892/etm.2019.8074.CrossRef

4.

Liang W, Zhao Y, Huang W, Gao Y, Xu W, Tao J, He J, et al. Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA). Theranostics. 2019;9:2056–70. https://doi.org/10.7150/thno.28119.CrossRefPubMedPubMedCentral

5.

Liu QX, Zhou D, Han TC, Lu X, Hou B, Li MY, Dai JG, et al. A Noninvasive Multianalytical Approach for Lung Cancer diagnosis of patients with pulmonary nodules. Adv Sci (Weinheim Baden-Wurttemberg Germany). 2021;8:2100104. https://doi.org/10.1002/advs.202100104.CrossRef

6.

Chen Y, Zitello E, Guo R, Deng Y. The function of LncRNAs and their role in the prediction, diagnosis, and prognosis of lung cancer. Clin Translational Med. 2021;11:e367. https://doi.org/10.1002/ctm2.367.CrossRef

7.

Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer, lung cancer (Amsterdam, Netherlands), 76 (2012) 138–43https://doi.org/10.1016/j.lungcan.2011.11.012.

8.

Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem. 2001;47:624–30.CrossRefPubMed

9.

Saeed MEM, Drif AI, Efferth T. Biomarker profiling revealed Carcinoembryonic Antigen as a target of artesunate in a ductal breast Cancer patient. Anticancer Res. 2022;42:3483–94. https://doi.org/10.21873/anticanres.15835.CrossRefPubMed

10.

Kõrv L, Vibo R, Mallene S, Kõrv J. High incidence of stroke in young adults in Tartu, Estonia, 2013 to 2017: a prospective population-based study. Eur J Neurol. 2021;28:1984–91. https://doi.org/10.1111/ene.14812.CrossRefPubMed

11.

Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022;15:131. https://doi.org/10.1186/s13045-022-01351-y.CrossRefPubMedPubMedCentral

12.

Preethi KA, Selvakumar SC, Ross K, Jayaraman S, Tusubira D, Sekar D. Liquid biopsy: exosomal microRNAs as novel diagnostic and prognostic biomarkers in cancer. Mol Cancer. 2022;21:54. https://doi.org/10.1186/s12943-022-01525-9.CrossRefPubMedPubMedCentral

13.

Wang K, Wang X, Pan Q, Zhao B. Liquid biopsy techniques and pancreatic cancer: diagnosis, monitoring, and evaluation. Mol Cancer. 2023;22:167. https://doi.org/10.1186/s12943-023-01870-3.CrossRefPubMedPubMedCentral

14.

Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB 3rd, Boland P, S., Kopetz, et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and rectal-anal Task forces whitepaper, Nature reviews. Clin Oncol. 2020;17:757–70. https://doi.org/10.1038/s41571-020-0392-0.

15.

Chang L, Li J, Zhang R. Liquid biopsy for early diagnosis of non-small cell lung carcinoma: recent research and detection technologies, Biochimica et biophysica acta. Reviews cancer. 2022;1877:188729. https://doi.org/10.1016/j.bbcan.2022.188729.CrossRef

16.

Cucchiara F, Petrini I, Romei C, Crucitta S, Lucchesi M, Valleggi S, et al. M. Del re, combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives. Pharmacol Res. 2021;169:105643. https://doi.org/10.1016/j.phrs.2021.105643.CrossRefPubMed

17.

Lin D, Shen L, Luo M, Zhang K, Li J, Yang Q, Zhou J, et al. Circulating tumor cells: biology and clinical significance. Signal Transduct Target Therapy. 2021;6:404. https://doi.org/10.1038/s41392-021-00817-8.CrossRef

18.

Stock C, Circulating Tumor Cells. : Does Ion Transport Contribute to Intravascular Survival, Adhesion, Extravasation, and Metastatic Organotropism? Reviews of physiology, biochemistry and pharmacology, 182 (2022) 139–175.https://doi.org/10.1007/112_2021_68.

19.

Menyailo ME, Bokova UA, Ivanyuk EE, Khozyainova AA, Denisov EV. Metastasis Prevention: focus on metastatic circulating tumor cells. Mol Diagn Ther. 2021;25:549–62. https://doi.org/10.1007/s40291-021-00543-5.CrossRefPubMed

20.

Dasgupta A, Lim AR, Ghajar CM. Circulating and disseminated tumor cells: harbingers or initiators of metastasis? Mol Oncol. 2017;11:40–61. https://doi.org/10.1002/1878-0261.12022.CrossRefPubMedPubMedCentral

21.

Gu X, Huang X, Zhang X, Wang C. Development and validation of a DNA methylation-related classifier of circulating Tumour cells to Predict Prognosis and to provide a therapeutic strategy in Lung Adenocarcinoma. Int J Biol Sci. 2022;18:4984–5000. https://doi.org/10.7150/ijbs.75284.CrossRefPubMedPubMedCentral

22.

Deng Z, Wu S, Wang Y, Shi D. Circulating tumor cell isolation for cancer diagnosis and prognosis, EBioMedicine, 83 (2022) 104237.https://doi.org/10.1016/j.ebiom.2022.104237.

23.

Yousefi M, Ghaffari P, Nosrati R, Dehghani S, Salmaninejad A, Abarghan YJ, Ghaffari SH. Prognostic and therapeutic significance of circulating tumor cells in patients with lung cancer. Cell Oncol (Dordrecht). 2020;43:31–49. https://doi.org/10.1007/s13402-019-00470-y.CrossRef

24.

Li Y, Tian X, Gao L, Jiang X, Fu R, Zhang T, Yang D, et al. Clinical significance of circulating tumor cells and tumor markers in the diagnosis of lung cancer. Cancer Med. 2019;8:3782–92. https://doi.org/10.1002/cam4.2286.CrossRefPubMedPubMedCentral

25.

Li W, Liu JB, Hou LK, Yu F, Zhang J, Wu W, Fu D, et al. Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring. Mol Cancer. 2022;21:25. https://doi.org/10.1186/s12943-022-01505-z.CrossRefPubMedPubMedCentral

26.

Neeves KB. Catch me if you can: isolating circulating tumor cells from flowing blood. Clin Chem. 2012;58:803–4. https://doi.org/10.1373/clinchem.2012.182600.CrossRefPubMed

27.

Adamczyk LA, Williams H, Frankow A, Ellis HP, Haynes HR, Perks C, Kurian KM, et al. Current understanding of circulating Tumor cells - potential value in malignancies of the Central Nervous System. Front Neurol. 2015;6:174. https://doi.org/10.3389/fneur.2015.00174.CrossRefPubMedPubMedCentral

28.

Seyfoori A, Seyyed Ebrahimi SA, Samandari M, Samiei E, Stefanek E, Garnis C, Akbari M. Microfluidic-assisted CTC isolation and in situ monitoring using smart magnetic microgels. Small. 2023;19:e2205320. https://doi.org/10.1002/smll.202205320.CrossRefPubMed

29.

Harouaka RA, Nisic M, Zheng SY. Circulating tumor cell enrichment based on physical properties. J Lab Autom. 2013;18:455–68. https://doi.org/10.1177/2211068213494391.CrossRefPubMed

30.

Lawrence R, Watters M, Davies CR, Pantel K, Lu YJ. Circulating tumour cells for early detection of clinically relevant cancer, Nature reviews. Clin Oncol. 2023;20:487–500. https://doi.org/10.1038/s41571-023-00781-y.CrossRef

31.

Muchlińska A, Smentoch J, Żaczek AJ, Bednarz-Knoll N. Detection and characterization of circulating Tumor cells using imaging Flow Cytometry-A Perspective Study, Cancers, 14 (2022).https://doi.org/10.3390/cancers14174178.

32.

Jueckstock J, Rack B, Friedl TW, Scholz C, Steidl J, Trapp E, Janni W, et al. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - results of the German SUCCESS-A- trial. BMC Cancer. 2016;16:401. https://doi.org/10.1186/s12885-016-2454-3.CrossRefPubMedPubMedCentral

33.

Ramirez AB, Bhat R, Sahay D, De Angelis C, Thangavel H, Hedayatpour S, Trivedi MV, et al. Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis. BMC Cancer. 2019;19:220. https://doi.org/10.1186/s12885-019-5382-1.CrossRefPubMedPubMedCentral

34.

Choi YH, Hong TH, Yoon SB, Lee IS, Lee MA, Choi HJ, Jung ES et al. Prognostic implications of portal venous circulating tumor cells in Resectable Pancreatic Cancer, Biomedicines, 10 (2022).https://doi.org/10.3390/biomedicines10061289.

35.

Aoki M, Shoji H, Kashiro A, Takeuchi K, Shimizu Y, Honda K. Prospects for comprehensive analyses of circulating Tumor cells in Tumor Biology, Cancers, 12 (2020).https://doi.org/10.3390/cancers12051135.

36.

Corcoran RB, Chabner BA. Application of cell-free DNA analysis to Cancer Treatment, the New England journal of medicine, 379 (2018) 1754–65https://doi.org/10.1056/NEJMra1706174.

37.

Moding EJ, Nabet BY, Alizadeh AA, Diehn M. Detecting liquid remnants of solid tumors: circulating Tumor DNA minimal residual disease, Cancer discovery, 11 (2021) 2968–86https://doi.org/10.1158/2159-8290.Cd-21-0634.

38.

Dang DK, Park BH. Circulating tumor DNA: current challenges for clinical utility. J Clin Investig. 2022;132. https://doi.org/10.1172/jci154941.

39.

Li YZ, Kong SN, Liu YP, Yang Y, Zhang HM. Can Liquid Biopsy based on ctDNA/cfDNA replace tissue biopsy for the Precision treatment of EGFR-Mutated NSCLC? J Clin Med. 2023;12. https://doi.org/10.3390/jcm12041438.

40.

Wen X, Pu H, Liu Q, Guo Z, Luo D. Circulating Tumor DNA-A Novel Biomarker of Tumor Progression and its favorable detection techniques, cancers, 14 (2022).https://doi.org/10.3390/cancers14246025.

41.

Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, et al. C. Lindbjerg Andersen, analysis of plasma cell-free DNA by Ultradeep sequencing in patients with stages I to III colorectal Cancer. JAMA Oncol. 2019;5:1124–31. https://doi.org/10.1001/jamaoncol.2019.0528.CrossRefPubMedPubMedCentral

42.

Lamb YN, Dhillon S. Epi proColon(®) 2.0 CE: a blood-based screening test for Colorectal Cancer. Mol Diagn Ther. 2017;21:225–32. https://doi.org/10.1007/s40291-017-0259-y.CrossRefPubMed

43.

Araki K, Kurosawa A, Kumon H. Development of a quantitative methylation-specific droplet digital PCR assay for detecting Dickkopf-related protein 3. BMC Res Notes. 2022;15:169. https://doi.org/10.1186/s13104-022-06056-6.CrossRefPubMedPubMedCentral

44.

Xu L, Yu W, Xiao H, Lin K. BIRC5 is a prognostic biomarker associated with tumor immune cell infiltration. Sci Rep. 2021;11:390. https://doi.org/10.1038/s41598-020-79736-7.CrossRefPubMedPubMedCentral

45.

Emaus MN, Anderson JL. Allelic discrimination between circulating tumor DNA fragments enabled by a multiplex-qPCR assay containing DNA-enriched magnetic ionic liquids. Anal Chim Acta. 2020;1124:184–93. https://doi.org/10.1016/j.aca.2020.04.078.CrossRefPubMed

46.

Xu W, Shen P, Li R, Liu B, Yang L. Development of an Event-Specific Droplet Digital PCR Assay for quantification and evaluation of the transgene DNAs in Trace samples of GM PRNP-Knockout Goat, Foods (Basel, Switzerland), 11 (2022).https://doi.org/10.3390/foods11060868.

47.

Zhang YT, Dong M, Xu PP, Cai JH, Liu SH, Gao YB, Biointerfaces et al. 218 (2022) 112733.https://doi.org/10.1016/j.colsurfb.2022.112733.

48.

Shen Y, Bai X, Zhou X, Wang J, Guo N, Deng Y. Whole-genome analysis of Starmerella bacillaris CC-PT4 against MRSA, a Non-saccharomyces yeast isolated from grape. J fungi (Basel Switzerland). 2022;8. https://doi.org/10.3390/jof8121255.

49.

Wang BR, Chu DX, Cheng MY, Jin Y, Luo HG, Li N. Progress of HOTAIR-microRNA in hepatocellular carcinoma, Hereditary cancer in clinical practice, 20 (2022) 4.https://doi.org/10.1186/s13053-022-00210-8.

50.

Li J, Hu L, Tian C, Lu F, Wu J, Liu L. microRNA-150 promotes cervical cancer cell growth and survival by targeting FOXO4. BMC Mol Biol. 2015;16:24. https://doi.org/10.1186/s12867-015-0052-6.CrossRefPubMedPubMedCentral

51.

Wijewardene AA, Chehade M, Gild ML, Clifton-Bligh RJ, Bullock M. Translational Util Liquid Biopsies Thyroid Cancer Manage Cancers. 2021;13. https://doi.org/10.3390/cancers13143443.

52.

Wu S, Shen W, Yang L, Zhu M, Zhang M, Zong F, Wu J, et al. Genetic variations in miR-125 family and the survival of non-small cell lung cancer in Chinese population. Cancer Med. 2019;8:2636–45. https://doi.org/10.1002/cam4.2073.CrossRefPubMedPubMedCentral

53.

Ren W, Hou J, Yang C, Wang H, Wu S, Wu Y, Lu C, et al. Extracellular vesicles secreted by hypoxia pre-challenged mesenchymal stem cells promote non-small cell lung cancer cell growth and mobility as well as macrophage M2 polarization via mir-21-5p delivery. J Experimental Clin cancer Research: CR. 2019;38:62. https://doi.org/10.1186/s13046-019-1027-0.CrossRefPubMedCentral

54.

Jiang M, Qi F, Zhang K, Zhang X, Ma J, Xia S, Chen D et al. MARCKSL1-2 reverses docetaxel-resistance of lung adenocarcinoma cells by recruiting SUZ12 to suppress HDAC1 and elevate miR-200b, molecular cancer, 21 (2022) 150https://doi.org/10.1186/s12943-022-01605-w.

55.

Zhang R, Pan T, Xiang Y, Zhang M, Xie H, Liang Z et al. X. Sui, Curcumenol triggered ferroptosis in lung cancer cells via lncRNA H19/miR-19b-3p/FTH1 axis, bioactive materials, 13 (2022) 23–36https://doi.org/10.1016/j.bioactmat.2021.11.013.

56.

Su W, Feng S, Chen X, Yang X, Mao R, Guo C, Chen G et al. Silencing of long noncoding RNA MIR22HG triggers cell Survival/Death signaling via oncogenes YBX1, MET, and p21 in Lung Cancer, Cancer research, 78 (2018) 3207–19https://doi.org/10.1158/0008-5472.Can-18-0222.

57.

Zhang L, Hu J, Li J, Yang Q, Hao M, Bu L. Long noncoding RNA LINC-PINT inhibits non-small cell lung cancer progression through sponging miR-218-5p/PDCD4, Artificial cells, nanomedicine, and biotechnology, 47 (2019) 1595–602https://doi.org/10.1080/21691401.2019.1605371.

58.

Liu R, Chang W, Li J, Cheng Y, Dang E, Yang X, Zhang K et al. Mesenchymal stem cells in psoriatic lesions affect the skin microenvironment through circular RNA, experimental dermatology, 28 (2019) 292–9https://doi.org/10.1111/exd.13890.

59.

Zhang N, Nan A, Chen L, Li X, Jia Y, Qiu M, Jiang Y, et al. Circular RNA circSATB2 promotes progression of non-small cell lung cancer cells. Mol Cancer. 2020;19:101. https://doi.org/10.1186/s12943-020-01221-6.CrossRefPubMedPubMedCentral

60.

Zhang LX, Gao J, Long X, Zhang PF, Yang X, Zhu SQ, Wu YB et al. The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis, molecular cancer, 21 (2022) 110.https://doi.org/10.1186/s12943-022-01586-w.

61.

Nie J, Yang R, Zhou R, Deng Y, Li D, Gou D, Zhang Y. Circular RNA circFARSA promotes the tumorigenesis of non-small cell lung cancer by elevating B7H3 via sponging miR-15a-5p, cell cycle (Georgetown, Tex.), 21 (2022) 2575–89https://doi.org/10.1080/15384101.2022.2105087.

62.

He Q, Liu L, Wang Y, Xu C, Xu M, Fu J, Ni H, et al. Mir-155-5p in the spinal cord regulates hypersensitivity in a rat model of bone cancer pain. Mol Pain. 2022;18:17448069221127811. https://doi.org/10.1177/17448069221127811.CrossRefPubMedPubMedCentral

63.

Jiang C, Hu X, Alattar M, Zhao H. miRNA expression profiles associated with diagnosis and prognosis in lung cancer. Expert Rev Anticancer Ther. 2014;14:453–61. https://doi.org/10.1586/14737140.2013.870037.CrossRefPubMed

64.

Zhang F, Guo J, Zhang Z, Duan M, Wang G, Qian Y, Jiang X, et al. Application of engineered extracellular vesicles for targeted tumor therapy. J Biomed Sci. 2022;29:14. https://doi.org/10.1186/s12929-022-00798-y.CrossRefPubMedPubMedCentral

65.

Zhang F, Guo J, Zhang Z, Qian Y, Wang G, Duan M, Jiang X, et al. Mesenchymal stem cell-derived exosome: a tumor regulator and carrier for targeted tumor therapy. Cancer Lett. 2022;526:29–40. https://doi.org/10.1016/j.canlet.2021.11.015.CrossRefPubMed

66.

Ahmadi M, Mahmoodi M, Shoaran M, Nazari-Khanamiri F, Rezaie J. Harnessing Normal and Engineered Mesenchymal stem cells derived exosomes for Cancer Therapy: Opportunity and challenges. Int J Mol Sci. 2022;23. https://doi.org/10.3390/ijms232213974.

67.

Meng Y, Bian L, Zhang M, Bo F, Lu X, Li D. Liquid biopsy and their application progress in head and neck cancer: focus on biomarkers CTCs, cfDNA, ctDNA and EVs, biomarkers in medicine, 14 (2020) 1393–404https://doi.org/10.2217/bmm-2020-0022.

68.

Hsu XR, Wu JE, Wu YY, Hsiao SY, Liang JL, Wu YJ, Hong TM, et al. Exosomal long noncoding RNA MLETA1 promotes tumor progression and metastasis by regulating the miR-186-5p/EGFR and miR-497-5p/IGF1R axes in non-small cell lung cancer. J Experimental Clin cancer Research: CR. 2023;42:283. https://doi.org/10.1186/s13046-023-02859-y.CrossRefPubMedCentral

69.

Yan Y, Du C, Duan X, Yao X, Wan J, Jiang Z, Qin Z, et al. Inhibiting collagen I production and tumor cell colonization in the lung via miR-29a-3p loading of exosome-/liposome-based nanovesicles. Acta Pharm Sinica B. 2022;12:939–51. https://doi.org/10.1016/j.apsb.2021.08.011.CrossRef

70.

Chen SW, Zhu SQ, Pei X, Qiu BQ, Xiong D, Long X, Wu YB et al. Cancer cell-derived exosomal circUSP7 induces CD8(+) T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC, Molecular cancer, 20 (2021) 144.https://doi.org/10.1186/s12943-021-01448-x.

71.

Hsu CC, Yang Y, Kannisto E, Zeng X, Yu G, Patnaik SK, Wu Y et al. Simultaneous detection of Tumor Derived Exosomal Protein-MicroRNA pairs with an Exo-PROS Biosensor for Cancer diagnosis, ACS nano, 17 (2023) 8108–22https://doi.org/10.1021/acsnano.2c10970.

72.

Zang X, Gu J, Zhang J, Shi H, Hou S, Xu X, Zhang X, et al. Exosome-transmitted lncRNA UFC1 promotes non-small-cell lung cancer progression by EZH2-mediated epigenetic silencing of PTEN expression. Cell Death Dis. 2020;11:215. https://doi.org/10.1038/s41419-020-2409-0.CrossRefPubMedPubMedCentral

73.

Chen X, Wang K. lncRNA ZEB2-AS1 aggravates progression of Non-small Cell Lung Carcinoma via suppressing PTEN Level, Medical science monitor: international medical journal of experimental and clinical research, 25 (2019) 8363–70https://doi.org/10.12659/msm.918922.

74.

Grosser B, Glückstein MI, Dhillon C, Schiele S, Dintner S, VanSchoiack A, et al. B. Märkl, Stroma Areactive Invasion Front Areas (SARIFA) - a new prognostic biomarker in gastric cancer related to tumor-promoting adipocytes. J Pathol. 2021. https://doi.org/10.1002/path.5810.CrossRefPubMed

75.

Zeringer E, Barta T, Li M, Vlassov AV. Strategies for isolation of exosomes, Cold Spring Harbor protocols, 2015 (2015) 319–323.https://doi.org/10.1101/pdb.top074476.

76.

Irmer B, Chandrabalan S, Maas L, Bleckmann A, Menck K. Extracellular vesicles in Liquid biopsies as biomarkers for solid tumors. Cancers; 2023. p. 15. https://doi.org/10.3390/cancers15041307.

77.

Takahashi H, Yasui T, Hirano M, Shinjo K, Miyazaki Y, Shinoda W, Baba Y, et al. Biosens Bioelectron. 2023;234. https://doi.org/10.1016/j.bios.2023.115318. Mutation detection of urinary cell-free DNA via catch-and-release isolation on nanowires for liquid biopsy.

78.

Yang F, Liao X, Tian Y, Li G. Exosome separation using microfluidic systems: size-based, immunoaffinity-based and dynamic methodologies. Biotechnol J. 2017;12. https://doi.org/10.1002/biot.201600699.

79.

Wei Y, Wang D, Jin F, Bian Z, Li L, Liang H, Zen K, et al. Pyruvate kinase type M2 promotes tumour cell exosome release via phosphorylating synaptosome-associated protein 23. Nat Commun. 2017;8:14041. https://doi.org/10.1038/ncomms14041.CrossRefPubMedPubMedCentral

80.

Choi D, Montermini L, Jeong H, Sharma S, Meehan B, Rak J. Mapping subpopulations of Cancer Cell-Derived Extracellular vesicles and particles by Nano-Flow Cytometry. ACS Nano. 2019;13:10499–511. https://doi.org/10.1021/acsnano.9b04480.CrossRefPubMed

81.

Bagheri Hashkavayi A, Cha BS, Lee ES, Kim S, Park KS. Advances in Exosome Analysis Methods with an Emphasis on Electrochemistry, Analytical chemistry, 92 (2020) 12733–12740.https://doi.org/10.1021/acs.analchem.0c02745.

82.

Gao Y, Liu CJ, Li HY, Xiong XM, Li GL, Gao S et al. Platelet RNA enables accurate detection of ovarian cancer: an intercontinental, biomarker identification study, Protein & cell, 14 (2023) 579–590.https://doi.org/10.1093/procel/pwac056.

83.

Joosse SA, Pantel K. Tumor-educated platelets as Liquid Biopsy in Cancer patients, Cancer cell, 28 (2015) 552–4https://doi.org/10.1016/j.ccell.2015.10.007.

84.

Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Sood AK, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366:610–8. https://doi.org/10.1056/NEJMoa1110352.CrossRefPubMedPubMedCentral

85.

Best MG, Wesseling P, Wurdinger T. Tumor-educated platelets as a noninvasive biomarker source for Cancer Detection and Progression Monitoring. Cancer Res. 2018;78:3407–12. https://doi.org/10.1158/0008-5472.Can-18-0887.CrossRefPubMed

86.

Rachidi S, Metelli A, Riesenberg B, Wu BX, Nelson MH, Wallace C, Li Z, et al. Platelets subvert T cell immunity against cancer via GARP-TGFβ axis. Sci Immunol. 2017;2. https://doi.org/10.1126/sciimmunol.aai7911.

87.

Pucci F, Rickelt S, Newton AP, Garris C, Nunes E, Evavold C, Pittet MJ et al. PF4 promotes platelet production and lung Cancer growth, cell reports, 17 (2016) 1764–72https://doi.org/10.1016/j.celrep.2016.10.031.

88.

Nilsson RJ, Karachaliou N, Berenguer J, Gimenez-Capitan A, Schellen P, Teixido C, Wurdinger T, et al. Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. Oncotarget. 2016;7:1066–75. https://doi.org/10.18632/oncotarget.6279.CrossRefPubMed

89.

Bray PF, McKenzie SE, Edelstein LC, Nagalla S, Delgrosso K, Ertel A, Rigoutsos I, et al. The complex transcriptional landscape of the anucleate human platelet. BMC Genomics. 2013;14:1. https://doi.org/10.1186/1471-2164-14-1.CrossRefPubMedPubMedCentral

90.

Edelstein LC, Simon LM, Montoya RT, Holinstat M, Chen ES, Bergeron A, Bray PF et al. Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c, Nature medicine, 19 (2013) 1609–16https://doi.org/10.1038/nm.3385.

91.

Rowley JW, Oler AJ, Tolley ND, Hunter BN, Low EN, Nix DA, Weyrich AS, et al. Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. Blood. 2011;118:e101–111. https://doi.org/10.1182/blood-2011-03-339705.CrossRefPubMedPubMedCentral

92.

Best MG. S. In ‘t Veld, N. Sol, T. Wurdinger, RNA sequencing and swarm intelligence-enhanced classification algorithm development for blood-based disease diagnostics using spliced blood platelet RNA, Nature protocols, 14 (2019) 1206–1234.https://doi.org/10.1038/s41596-019-0139-5.

93.

Liu L, Lin F, Ma X, Chen Z, Yu J. Tumor-educated platelet as liquid biopsy in lung cancer patients. Crit Rev Oncol/Hematol. 2020;146:102863. https://doi.org/10.1016/j.critrevonc.2020.102863.CrossRefPubMed

94.

Rikkert LG, van der Pol E, van Leeuwen TG, Nieuwland R, Coumans FAW. Centrifugation affects the purity of liquid biopsy-based tumor biomarkers. Cytometry Part A: J Int Soc Anal Cytol. 2018;93:1207–12. https://doi.org/10.1002/cyto.a.23641.CrossRef

95.

Mazzone PJ, Wang XF, Beukemann M, Zhang Q, Seeley M, Mohney R, Pappan KL, et al. Metabolite profiles of the serum of patients with Non-small Cell Carcinoma. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2016;11:72–8. https://doi.org/10.1016/j.jtho.2015.09.002.CrossRef

96.

Yang M, Soga T, Pollard PJ. Oncometabolites: linking altered metabolism with cancer. J Clin Investig. 2013;123:3652–8. https://doi.org/10.1172/jci67228.CrossRefPubMedPubMedCentral

97.

Sulkowski PL, Oeck S, Dow J, Economos NG, Mirfakhraie L, Liu Y, Glazer PM, et al. Oncometabolites suppress DNA repair by disrupting local chromatin signalling. Nature. 2020;582:586–91. https://doi.org/10.1038/s41586-020-2363-0.CrossRefPubMedPubMedCentral

98.

Wang ZH, Peng WB, Zhang P, Yang XP, Zhou Q. Lactate in the tumour microenvironment: from immune modulation to therapy, EBioMedicine, 73 (2021) 103627https://doi.org/10.1016/j.ebiom.2021.103627.

99.

Du D, Liu C, Qin M, Zhang X, Xi T, Yuan S, et al. J. Xiong, metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharm Sinica B. 2022;12:558–80. https://doi.org/10.1016/j.apsb.2021.09.019.CrossRef

100.

Zheng J, Zheng Y, Li W, Zhi J, Huang X, Zhu W, Gong L et al. Combined metabolomics with transcriptomics reveals potential plasma biomarkers correlated with non-small-cell lung cancer proliferation through the akt pathway, Clinica Chimica acta; international journal of clinical chemistry, 530 (2022) 66–73https://doi.org/10.1016/j.cca.2022.02.018.

101.

Chuang SC, Fanidi A, Ueland PM, Relton C, Midttun O, Vollset SE, Johansson M et al. Circulating biomarkers of tryptophan and the kynurenine pathway and lung cancer risk, Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 23 (2014) 461–8https://doi.org/10.1158/1055-9965.Epi-13-0770.

102.

Sivanand S, Vander Heiden MG. Emerging roles for branched-chain amino acid metabolism in Cancer, Cancer cell, 37 (2020) 147–56https://doi.org/10.1016/j.ccell.2019.12.011.

103.

Emwas AH, The strengths and weaknesses of NMR spectroscopy and mass spectrometry with particular focus on metabolomics research, Methods in molecular biology (, Clifton NJ.), 1277 (2015) 161–193.https://doi.org/10.1007/978-1-4939-2377-9_13.

104.

Nagana Gowda GA, Raftery D. NMR metabolomics methods for investigating Disease. Anal Chem. 2023;95:83–99. https://doi.org/10.1021/acs.analchem.2c04606.CrossRefPubMedPubMedCentral

105.

Cui P, Li X, Huang C, Li Q, Lin D. Metabolomics and its applications in Cancer Cachexia. Front Mol Biosci. 2022;9:789889. https://doi.org/10.3389/fmolb.2022.789889.CrossRefPubMedPubMedCentral

106.

Wang R, Yin Y, Zhu ZJ. Advancing untargeted metabolomics using data-independent acquisition mass spectrometry technology, Analytical and bioanalytical chemistry, 411 (2019) 4349–57https://doi.org/10.1007/s00216-019-01709-1.

107.

Delvaux A, Rathahao-Paris E, Alves S. Different ion mobility-mass spectrometry coupling techniques to promote metabolomics. Mass Spectrom Rev. 2022;41:695–721. https://doi.org/10.1002/mas.21685.CrossRefPubMed

108.

Teav T, Gallart-Ayala H, van der Velpen V, Mehl F, Henry H, Ivanisevic J. Merged targeted quantification and untargeted profiling for Comprehensive Assessment of acylcarnitine and amino acid metabolism. Anal Chem. 2019;91:11757–69. https://doi.org/10.1021/acs.analchem.9b02373.CrossRefPubMed

109.

Schmidt DR, Patel R, Kirsch DG, Lewis CA, Vander Heiden MG, Locasale JW. Metabolomics in cancer research and emerging applications in clinical oncology, CA: a cancer journal for clinicians, 71 (2021) 333–58https://doi.org/10.3322/caac.21670.

110.

Li P, Shi JX, Xing MT, Dai LP, Li JT, Zhang JY. Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer.

111.

Blagih J, Buck MD, Vousden KA-O. p53, cancer and the immune response. LID - jcs237453 [pii] LID – 10.1242/jcs.237453 [doi],.

112.

Shan Q, Lou T, Fau - X, Xiao J, Xiao T, Fau - Zhang H, Zhang J, Fau - Sun Y, Sun H, Fau - Gao S, Gao Y, Fau - Cheng S, Liu et al. A cancer/testis antigen microarray to screen autoantibody biomarkers of non-small cell lung cancer.

113.

Kobayashi M, Katayama H, Fahrmann JF, Hanash SM. Development of autoantibody signatures for common cancers.

114.

Li G, Miles A, Fau - A, Line RC, Line A, Fau - Rees RC, Rees. Identification of tumour antigens by serological analysis of cDNA expression cloning.

115.

Zhong L, Peng GE, Fau X, Hidalgo DE, Hidalgo Ge Fau - Doherty AJ Doherty De Fau - Stromberg, E.A. Stromberg Aj Fau - Hirschowitz, Hirschowitz EA. Identification of circulating antibodies to tumor-associated proteins for combined use as markers of non-small cell lung cancer.

116.

Kniemeyer O, Ebel F, Krüger T, Bacher P, Scheffold A, Luo T, Brakhage AA et al. Immunoproteomics of Aspergillus for the development of biomarkers and immunotherapies.

117.

Zhong L, Hidalgo Ge Fau AJ, Stromberg NH, Stromberg Aj Fau - Khattar JR, Jett EA Jr, Hirschowitz F, Hirschowitz EA. Using protein microarray as a diagnostic assay for non-small cell lung cancer.

118.

Wilson B, Becker A, Estes T, Keshavamurthy J, Pucar D. Adrenal hemangioma definite diagnosis on CT, MRI, and FDG PET in a patient with primary Lung Cancer, Clinical nuclear medicine, 43 (2018) e192–4.https://doi.org/10.1097/rlu.0000000000002069.

119.

Li P, Liu S, Du L, Mohseni G, Zhang Y, Wang C. Liquid biopsies based on DNA methylation as biomarkers for the detection and prognosis of lung cancer. Clin Epigenetics. 2022;14:118. https://doi.org/10.1186/s13148-022-01337-0.CrossRefPubMedPubMedCentral

120.

Kapeleris J, Kulasinghe A, Warkiani ME, Vela I, Kenny L, O’Byrne K, Punyadeera C. The Prognostic Role of circulating Tumor cells (CTCs) in Lung Cancer. Front Oncol. 2018;8:311. https://doi.org/10.3389/fonc.2018.00311.CrossRefPubMedPubMedCentral

121.

Gasiorowski L, Dyszkiewicz W, Zielinski P. In-vivo isolation of circulating tumor cells in non-small cell lung cancer patients by CellCollector. Neoplasma. 2017;64:938–44. https://doi.org/10.4149/neo_2017_618.CrossRefPubMed

122.

Gorges TM, Penkalla N, Schalk T, Joosse SA, Riethdorf S, Tucholski J, Pantel K et al. Enumeration and molecular characterization of Tumor cells in Lung Cancer patients using a novel in vivo device for capturing circulating Tumor cells, clinical cancer research: an official journal of the American Association for Cancer Research, 22 (2016) 2197–206https://doi.org/10.1158/1078-0432.Ccr-15-1416.

123.

Pfarr N, Penzel R, Klauschen F, Heim D, Brandt R, Kazdal D, Stenzinger A, et al. Copy number changes of clinically actionable genes in melanoma, non-small cell lung cancer and colorectal cancer-A survey across 822 routine diagnostic cases. Genes Chromosomes Cancer. 2016;55:821–33. https://doi.org/10.1002/gcc.22378.CrossRefPubMed

124.

Yang D, Yang X, Li Y, Zhao P, Fu R, Ren T, Guo N, et al. Clinical significance of circulating tumor cells and metabolic signatures in lung cancer after surgical removal. J Translational Med. 2020;18:243. https://doi.org/10.1186/s12967-020-02401-0.CrossRef

125.

Nicolazzo C, Barault L, Caponnetto S, De Renzi G, Belardinilli F, Bottillo I, Gazzaniga P, et al. True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature. Cancer Lett. 2021;507:89–96. https://doi.org/10.1016/j.canlet.2021.03.014.CrossRefPubMed

126.

Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, Diehn M, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20:548–54. https://doi.org/10.1038/nm.3519.CrossRefPubMedPubMedCentral

127.

Szczerba BM, Castro-Giner F, Vetter M, Krol I, Gkountela S, Landin J, et al. N. Aceto, neutrophils escort circulating tumour cells to enable cell cycle progression. Nature. 2019;566:553–7. https://doi.org/10.1038/s41586-019-0915-y.CrossRefPubMed

128.

Guan X, Liu B, Niu Y, Dong X, Zhu X, Li C, Ma F, et al. Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer. Breast (Edinburgh Scotland). 2020;49:261–6. https://doi.org/10.1016/j.breast.2019.12.010.CrossRefPubMed

129.

Park S, Lee SY, Kim D, Sim YS, Ryu JS, Choi J, Chang JH, et al. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types. BMC Cancer. 2021;21:52. https://doi.org/10.1186/s12885-020-07765-6.CrossRefPubMedPubMedCentral

130.

Zhang WC, Chin TM, Yang H, Nga ME, Lunny DP, Lim EK, Lim B, et al. Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression. Nat Commun. 2016;7. https://doi.org/10.1038/ncomms11702.

131.

Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Weidhaas JB, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3’ untranslated region increases non-small cell lung cancer risk. Cancer Res. 2008;68:8535–40. https://doi.org/10.1158/0008-5472.Can-08-2129.CrossRefPubMedPubMedCentral

132.

Abdollahi A, Rahmati S, Ghaderi B, Sigari N, Nikkhoo B, Sharifi K, Abdi M. A combined panel of circulating microRNA as a diagnostic tool for detection of the non-small cell lung cancer. QJM: Monthly J Association Physicians. 2019;112:779–85. https://doi.org/10.1093/qjmed/hcz158.CrossRef

133.

Sun Y, Fang L, Yi Y, Feng A, Zhang K, Xu JJ. Multistage nucleic acid amplification induced nano-aggregation for 3D hotspots-improved SERS detection of circulating miRNAs. J Nanobiotechnol. 2022;20:285. https://doi.org/10.1186/s12951-022-01500-y.CrossRef

134.

Zuo YB, Zhang YF, Zhang R, Tian JW, Lv XB, Li R, et al. H. Xin, Ferroptosis in Cancer Progression: role of noncoding RNAs. Int J Biol Sci. 2022;18:1829–43. https://doi.org/10.7150/ijbs.66917.CrossRefPubMedPubMedCentral

135.

Gao Y, Zhang N, Zeng Z, Wu Q, Jiang X, Li S, Xie C, et al. LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non-small cell lung cancer. Clin Translational Med. 2022;12:e792. https://doi.org/10.1002/ctm2.792.CrossRef

136.

Chen T, Liu Y, Li C, Xu C, Ding C, Chen J, Zhao J. Tumor-derived exosomal circFARSA mediates M2 macrophage polarization via the PTEN/PI3K/AKT pathway to promote non-small cell lung cancer metastasis. Cancer Treat Res Commun. 2021;28:100412. https://doi.org/10.1016/j.ctarc.2021.100412.CrossRefPubMed

137.

Zhang W, Campbell DH, Walsh BJ, Packer NH, Liu D, Wang Y. Cancer-derived small extracellular vesicles: emerging biomarkers and therapies for pancreatic ductal adenocarcinoma diagnosis/prognosis and treatment. J Nanobiotechnol. 2022;20:446. https://doi.org/10.1186/s12951-022-01641-0.CrossRef

138.

Yuan L, Chen Y, Ke L, Zhou Q, Chen J, Fan M, Wang J, et al. Plasma extracellular vesicle phenotyping for the differentiation of early-stage lung cancer and benign lung diseases. Nanoscale Horizons. 2023;8:746–58. https://doi.org/10.1039/d2nh00570k.CrossRefPubMed

139.

Zhong Y, Ding X, Bian Y, Wang J, Zhou W, Wang X, Wang C, et al. Discovery and validation of extracellular vesicle-associated miRNAs as noninvasive detection biomarkers for early-stage non-small-cell lung cancer. Mol Oncol. 2021;15:2439–52. https://doi.org/10.1002/1878-0261.12889.CrossRefPubMedPubMedCentral

140.

Zhang Y, Liu W, Zhang H, Sun B, Chen T, Hu M, Wu L, et al. Extracellular vesicle long RNA markers of early-stage lung adenocarcinoma. Int J Cancer. 2023;152:1490–500. https://doi.org/10.1002/ijc.34386.CrossRefPubMed

141.

Qi SA, Wu Q, Chen Z, Zhang W, Zhou Y, Mao K, Huang Y, et al. High-resolution metabolomic biomarkers for lung cancer diagnosis and prognosis. Sci Rep. 2021;11:11805. https://doi.org/10.1038/s41598-021-91276-2.CrossRefPubMedPubMedCentral

142.

Guan X, Du Y, Ma R, Teng N, Ou S, Zhao H, Li X. Construction of the XGBoost model for early lung cancer prediction based on metabolic indices, BMC medical informatics and decision making, 23 (2023) 107.https://doi.org/10.1186/s12911-023-02171-x.

143.

Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, Soga T, et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 2009;69:4918–25. https://doi.org/10.1158/0008-5472.Can-08-4806.CrossRefPubMed

144.

Dai C, Arceo J, Arnold J, Sreekumar A, Dovichi NJ, Li J, Littlepage LE. Metabolomics of oncogene-specific metabolic reprogramming during breast cancer. Cancer Metabolism. 2018;6:5. https://doi.org/10.1186/s40170-018-0175-6.CrossRefPubMedPubMedCentral

145.

D’Ambrosi S, Nilsson RJ, Wurdinger T. Platelets and tumor-associated RNA transfer. Blood. 2021;137:3181–91. https://doi.org/10.1182/blood.2019003978.CrossRefPubMedPubMedCentral

146.

Dong X, Song X, Ding S, Yu M, Shang X, Wang K, Song X, et al. Tumor-educated platelet SNORD55 as a potential biomarker for the early diagnosis of non-small cell lung cancer. Thorac cancer. 2021;12:659–66. https://doi.org/10.1111/1759-7714.13823.CrossRefPubMedPubMedCentral

147.

D’Ambrosi S, Visser A, Antunes-Ferreira M, Poutsma A, Giannoukakos S, Sol N, Würdinger T et al. The analysis of platelet-derived circRNA repertoire as potential diagnostic biomarker for Non-small Cell Lung Cancer, Cancers, 13 (2021).https://doi.org/10.3390/cancers13184644.

148.

Xing S, Zeng T, Xue N, He Y, Lai YZ, Li HL, Liu WL, et al. Development and Validation of Tumor-educated blood platelets integrin alpha 2b (ITGA2B) RNA for diagnosis and prognosis of non-small-cell Lung Cancer through RNA-seq. Int J Biol Sci. 2019;15:1977–92. https://doi.org/10.7150/ijbs.36284.CrossRefPubMedPubMedCentral

149.

Yuan N, Xin GH, Zuo XX, Huang SK, Wang Y, Hou L, Zhao XH et al. [Combination of phage display and SEREX for screening early lung cancer associated antigens].

150.

Wang T, Liu H, Pei L, Wang K, Song C, Wang P, Dai L et al. Screening of tumor-associated antigens based on Oncomine database and evaluation of diagnostic value of autoantibodies in lung cancer.

151.

Seijo LM, Peled N, Ajona D, Boeri M, Field JK, Sozzi G et al. L.M. Montuenga, biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges.

152.

Russell É, Conroy MJ, Barr MP. Harnessing natural killer cells in Non-small Cell Lung Cancer, cells, 11 (2022).https://doi.org/10.3390/cells11040605.

153.

Kolenčík D, Narayan S, Thiele JA, McKinley D, Gerdtsson AS, Welter L et al. S.N. Shishido, Circulating Tumor Cell Kinetics and Morphology from the Liquid Biopsy Predict Disease Progression in Patients with Metastatic Colorectal Cancer Following Resection, Cancers, 14 (2022).https://doi.org/10.3390/cancers14030642.

154.

Beije N, Onstenk W, Kraan J, Sieuwerts AM, Hamberg P, Dirix LY, Sleijfer S et al. Prognostic impact of HER2 and ER status of circulating Tumor cells in metastatic breast Cancer patients with a HER2-Negative primary tumor, Neoplasia (New York, N.Y.), 18 (2016) 647–53https://doi.org/10.1016/j.neo.2016.08.007.

155.

Garrido-Navas MC, García-Díaz A, Molina-Vallejo MP, González-Martínez C, Alcaide Lucena M, Cañas-García I, Serrano MJ et al. The Polemic Diagnostic Role of TP53 Mutations in Liquid Biopsies from Breast, Colon and Lung Cancers, Cancers, 12 (2020).https://doi.org/10.3390/cancers12113343.

156.

Nicolazzo C, Raimondi C, Mancini M, Caponnetto S, Gradilone A, Gandini O, Gazzaniga P et al. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab, Scientific reports, 6 (2016) 31726.https://doi.org/10.1038/srep31726.

157.

Gardner KP, Tsai S, Aldakkak M, Gironda S, Adams DL. CXCR4 expression in tumor associated cells in blood is prognostic for progression and survival in pancreatic cancer. PLoS ONE. 2022;17:e0264763. https://doi.org/10.1371/journal.pone.0264763.CrossRefPubMedPubMedCentral

158.

Fusi A, Liu Z, Kümmerlen V, Nonnemacher A, Jeske J, Keilholz U. Expression of chemokine receptors on circulating tumor cells in patients with solid tumors. J Translational Med. 2012;10:52. https://doi.org/10.1186/1479-5876-10-52.CrossRef

159.

Wang Z, Zhang XC, Feng WN, Zhang L, Liu XQ, Guo WB, Wu YL, et al. Circulating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patients. Therapeutic Adv Med Oncol. 2023;15:17588359231167818. https://doi.org/10.1177/17588359231167818.CrossRef

160.

Xu Y, Ren X, Jiang T, Lv S, Gao K, Liu Y, Yan Y. Circulating tumor cells (CTCs) and hTERT gene expression in CTCs for radiotherapy effect with lung cancer. BMC Cancer. 2023;23:475. https://doi.org/10.1186/s12885-023-10979-z.CrossRefPubMedPubMedCentral

161.

Dall’Olio FG, Marabelle A, Caramella C, Garcia C, Aldea M, Chaput N, Besse B, et al. Tumour burden and efficacy of immune-checkpoint inhibitors, Nature reviews. Clin Oncol. 2022;19:75–90. https://doi.org/10.1038/s41571-021-00564-3.CrossRef

162.

Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Oxnard GR et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M, Nature medicine, 21 (2015) 560–2https://doi.org/10.1038/nm.3854.

163.

Ortiz-Cuaran S, Scheffler M, Plenker D, Dahmen L, Scheel AH, Fernandez-Cuesta L, Sos ML et al. Heterogeneous mechanisms of primary and Acquired Resistance to Third-Generation EGFR inhibitors, clinical cancer research: an official journal of the American Association for Cancer Research, 22 (2016) 4837–47https://doi.org/10.1158/1078-0432.Ccr-15-1915.

164.

Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Jänne PA, et al. Osimertinib in Pretreated T790M-Positive Advanced Non-small-cell Lung Cancer: AURA study phase II extension component. J Clin Oncology: Official J Am Soc Clin Oncol. 2017;35:1288–96. https://doi.org/10.1200/jco.2016.70.3223.CrossRef

165.

Goss G, Tsai CM, Shepherd FA, Bazhenova L, Lee JS, Chang GC, Mitsudomi T, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016;17:1643–52. https://doi.org/10.1016/s1470-2045(16)30508-3.CrossRefPubMed

166.

Vendrell JA, Quantin X, Serre I, Solassol J. Combination of tissue and liquid biopsy molecular profiling to detect transformation to small cell lung carcinoma during osimertinib treatment. Therapeutic Adv Med Oncol. 2020;12:1758835920974192. https://doi.org/10.1177/1758835920974192.CrossRef

167.

Verzè M, Pluchino M, Leonetti A, Corianò M, Bonatti F, Armillotta MP, Tiseo M, et al. Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review. Translational lung cancer Res. 2022;11:2588–600. https://doi.org/10.21037/tlcr-22-390.CrossRef

168.

Xia L, Mei J, Kang R, Deng S, Chen Y, Yang Y, Liu L et al. Perioperative ctDNA-Based molecular residual disease detection for Non-small Cell Lung Cancer: a prospective Multicenter Cohort Study (LUNGCA-1), clinical cancer research: an official journal of the American Association for Cancer Research, 28 (2022) 3308–17https://doi.org/10.1158/1078-0432.Ccr-21-3044.

169.

Shi L, Zhu W, Huang Y, Zhuo L, Wang S, Chen S, Ke B et al. Cancer-associated fibroblast-derived exosomal microRNA-20a suppresses the PTEN/PI3K-AKT pathway to promote the progression and chemoresistance of non-small cell lung cancer, clinical and translational medicine, 12 (2022) e989.https://doi.org/10.1002/ctm2.989.

170.

Gu YF, Zhang H, Su D, Mo ML, Song P, Zhang F, Zhang SC. miR-30b and miR-30c expression predicted response to tyrosine kinase inhibitors as first line treatment in non-small cell lung cancer. Chin Med J. 2013;126:4435–9.CrossRefPubMed

171.

Bache M, Kadler F, Struck O, Medenwald D, Ostheimer C, Güttler A, Vordermark D, et al. Correlation between circulating miR-16, miR-29a, miR-144 and miR-150, and the Radiotherapy Response and Survival of Non-small-cell Lung Cancer patients. Int J Mol Sci. 2023;24. https://doi.org/10.3390/ijms241612835.

172.

Shen Y, Wang S, Wu Y. A novel m6A-Related LncRNA signature for Predicting Prognosis, Chemotherapy and Immunotherapy Response in patients with lung adenocarcinoma, cells, 11 (2022).https://doi.org/10.3390/cells11152399.

173.

Ju Z, Lei M, Xuan L, Luo J, Zhou M, Wang Y, Huang R, et al. P53-response circRNA_0006420 aggravates lung cancer radiotherapy resistance by promoting formation of HUR/PTBP1 complex. J Adv Res. 2023. https://doi.org/10.1016/j.jare.2023.07.011.CrossRefPubMed

174.

Wu H, Mu X, Liu L, Wu H, Hu X, Chen L, Zhao Y et al. Bone marrow mesenchymal stem cells-derived exosomal microRNA-193a reduces cisplatin resistance of non-small cell lung cancer cells via targeting LRRC1, cell death & disease, 11 (2020) 801.https://doi.org/10.1038/s41419-020-02962-4.

175.

Qin X, Yu S, Zhou L, Shi M, Hu Y, Xu X, Feng J, et al. Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal mir-100-5p-dependent manner. Int J Nanomed. 2017;12:3721–33. https://doi.org/10.2147/ijn.S131516.CrossRef

176.

Lee CH, Bae JH, Choe EJ, Park JM, Park SS, Cho HJ, Baek MC et al. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1, Theranostics, 12 (2022) 1971–87https://doi.org/10.7150/thno.68864.

177.

Chen RL, Wang Z, Huang P, Sun CH, Yu WY, Zhang HH, He JQ, et al. Isovitexin potentiated the antitumor activity of cisplatin by inhibiting the glucose metabolism of lung cancer cells and reduced cisplatin-induced immunotoxicity in mice. Int Immunopharmacol. 2021;94:107357. https://doi.org/10.1016/j.intimp.2020.107357.CrossRefPubMed

178.

Kodama M, Oshikawa K, Shimizu H, Yoshioka S, Takahashi M, Izumi Y, Nakayama KI, et al. A shift in glutamine nitrogen metabolism contributes to the malignant progression of cancer. Nat Commun. 2020;11:1320. https://doi.org/10.1038/s41467-020-15136-9.CrossRefPubMedPubMedCentral

179.

Shai S, Patolsky F, Drori H, Scheinman EJ, Davidovits E, Davidovits G, Adir Y, et al. A novel, accurate, and non-invasive liquid biopsy test to measure cellular immune responses as a tool to diagnose early-stage lung cancer: a clinical trials study. Respir Res. 2023;24:52. https://doi.org/10.1186/s12931-023-02358-w.CrossRefPubMedPubMedCentral

180.

Li Z, Wang Z, Tang Y, Lu X, Chen J, Dong Y, Shi Q, et al. Liquid biopsy-based single-cell metabolic phenotyping of lung cancer patients for informative diagnostics. Nat Commun. 2019;10:3856. https://doi.org/10.1038/s41467-019-11808-3.CrossRefPubMedPubMedCentral

181.

Zhu M, Zeng Q, Fan T, Lei Y, Wang F, Zheng S, He J, et al. Clinical significance and immunometabolism landscapes of a Novel recurrence-Associated lipid metabolism signature in early-stage lung adenocarcinoma: a comprehensive analysis. Front Immunol. 2022;13:783495. https://doi.org/10.3389/fimmu.2022.783495.CrossRefPubMedPubMedCentral

182.

Zhou X, Zhou R, Rao X, Hong J, Li Q, Jie X, Wu G, et al. Activated amino acid response pathway generates apatinib resistance by reprograming glutamine metabolism in non-small-cell lung cancer. Cell Death Dis. 2022;13:636. https://doi.org/10.1038/s41419-022-05079-y.CrossRefPubMedPubMedCentral

183.

Park CK, Kim JE, Kim MS, Kho BG, Park HY, Kim TO, Kim YC, et al. Feasibility of liquid biopsy using plasma and platelets for detection of anaplastic lymphoma kinase rearrangements in non-small cell lung cancer. J Cancer Res Clin Oncol. 2019;145:2071–82. https://doi.org/10.1007/s00432-019-02944-w.CrossRefPubMedPubMedCentral

184.

Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Engelman JA, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 2012;4:120ra117. https://doi.org/10.1126/scitranslmed.3003316.CrossRef

185.

Liu L, Song X, Li X, Xue L, Ding S, Niu L, Song X, et al. A three-platelet mRNA set: MAX, MTURN and HLA-B as biomarker for lung cancer. J Cancer Res Clin Oncol. 2019;145:2713–23. https://doi.org/10.1007/s00432-019-03032-9.CrossRefPubMed

186.

Zhou J, Zhao J, Jia Q, Chu Q, Zhou F, Chu X et al. Su C, Peripheral blood autoantibodies against to Tumor-Associated Antigen Predict Clinical Outcome to Immune Checkpoint inhibitor-based treatment in Advanced Non-Small Cell Lung Cancer.

187.

Seager RJ, Senosain MF, Van Roey E, Gao S, DePietro P, Nesline MK et al. S.A.-O. Pabla, Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer.

188.

Handke NA, Rupp AA-O, Trimpop N, von Pawel J. S. Holdenrieder, Soluble High Mobility Group Box 1 (HMGB1) is a Promising Biomarker for Prediction of Therapy Response and Prognosis in Advanced Lung Cancer patients. LID – 10.3390/diagnostics11020356 [doi] LID – 356,.

189.

Chen X, Wang L, Su X, Luo SY, Tang X, Huang Y. Identification of potential target genes and crucial pathways in small cell lung cancer based on bioinformatic strategy and human samples. PLoS ONE. 2020;15:e0242194. https://doi.org/10.1371/journal.pone.0242194.CrossRefPubMedPubMedCentral

190.

Sawabata N, Nakamura T, Kawaguchi T, Watanabe T, Ouji NS, Ito T, Taniguchi S. Circulating tumor cells detected only after surgery for non-small cell lung cancer: is it a predictor of recurrence? J Thorac Disease. 2020;12:4623–32. https://doi.org/10.21037/jtd-20-1636.CrossRef

191.

Hiltermann TJN, Pore MM, van den Berg A, Timens W, Boezen HM, Liesker JJW, Groen HJM et al. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor, annals of oncology: official journal of the European Society for Medical Oncology, 23 (2012) 2937–42https://doi.org/10.1093/annonc/mds138.

192.

Lindsay CR, Faugeroux V, Michiels S, Pailler E, Facchinetti F, Ou D, Farace F, et al. A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups. Annals Oncology: Official J Eur Soc Med Oncol. 2017;28:1523–31. https://doi.org/10.1093/annonc/mdx156.CrossRef

193.

Ren L, Zhong X, Liu W, Xu D, Lei Y, Zhou J, Ke Z et al. Clinical significance of a circulating Tumor Cell-based Classifier in Stage IB Lung Adenocarcinoma: a Multicenter, Cohort Study, annals of surgery, 277 (2023) e439–48.https://doi.org/10.1097/sla.0000000000004780.

194.

Bayarri-Lara C, Ortega FG, Cueto A, de Ladrón JL, Puche J, Ruiz Zafra D, de Miguel-Pérez MJ, Serrano et al. Circulating Tumor cells identify early recurrence in patients with Non-small Cell Lung Cancer undergoing Radical Resection, PloS one, 11 (2016) e0148659.https://doi.org/10.1371/journal.pone.0148659.

195.

Hou JM, Krebs M, Ward T, Sloane R, Priest L, Hughes A, Dive C, et al. Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol. 2011;178:989–96. https://doi.org/10.1016/j.ajpath.2010.12.003.CrossRefPubMedPubMedCentral

196.

Wu CY, Lee CL, Wu CF, Fu JY, Yang CT, Wen CT, Hsieh JC et al. Circulating Tumor cells as a Tool of minimal residual disease can predict Lung Cancer recurrence: a longitudinal, prospective trial, Diagnostics (Basel, Switzerland), 10 (2020)https://doi.org/10.3390/diagnostics10030144.

197.

Ren J, He J, Zhang H, Xia Y, Hu Z, Loughran P, Tsung A et al. Platelet TLR4-ERK5 Axis facilitates NET-Mediated capturing of circulating Tumor cells and distant metastasis after Surgical stress, Cancer research, 81 (2021) 2373–85https://doi.org/10.1158/0008-5472.Can-20-3222.

198.

Mao C, Deng B. [Research advances in the mechanism of Invasion and Metastasis of circulating Tumor cells in Lung Cancer], Zhongguo Fei ai Za Zhi = Chinese journal of lung cancer, 23 (2020) 189–95https://doi.org/10.3779/j.issn.1009-3419.2020.03.09.

199.

Xie J, Yao W, Chen L, Zhu W, Liu Q, Geng G, Zhao J, et al. Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers. BMC Cancer. 2023;23:294. https://doi.org/10.1186/s12885-023-10674-z.CrossRefPubMedPubMedCentral

200.

Chiang CL, Ho HL, Yeh YC, Lee CC, Huang HC, Shen CI, Chou TY, et al. Prognosticators of osimertinib treatment outcomes in patients with EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis. J Cancer Res Clin Oncol. 2023;149:5–14. https://doi.org/10.1007/s00432-022-04396-1.CrossRefPubMed

201.

Li N, Wang BX, Li J, Shao Y, Li MT, Li JJ, Wang SY, et al. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer. Cancer. 2022;128:708–18. https://doi.org/10.1002/cncr.33985.CrossRefPubMed

202.

Lam VK, Zhang J, Wu CC, Tran HT, Li L, Diao L, Heymach JV, et al. Genotype-specific differences in circulating tumor DNA levels in Advanced NSCLC. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2021;16:601–9. https://doi.org/10.1016/j.jtho.2020.12.011.CrossRef

203.

Tsakonas G, Tadigotla V, Chakrabortty SK, Stragliotto G, Chan D, Lewensohn R, S., Ekman et al. Cerebrospinal fluid as a liquid biopsy for molecular characterization of brain metastasis in patients with non-small cell lung cancer, lung cancer (Amsterdam, Netherlands), 182 (2023) 107292.https://doi.org/10.1016/j.lungcan.2023.107292.

204.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Swanton C, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545:446–51. https://doi.org/10.1038/nature22364.CrossRefPubMedPubMedCentral

205.

Fan L, Li B, Li Z, Sun L. Identification of Autophagy related circRNA-miRNA-mRNA-Subtypes network with radiotherapy responses and Tumor Immune Microenvironment in Non-small Cell Lung Cancer, Frontiers in genetics, 12 (2021) 730003.https://doi.org/10.3389/fgene.2021.730003.

206.

Dai H, Li L, Yang Y, Chen H, Dong X, Mao Y, Gao Y. Screening microRNAs as potential prognostic biomarkers for lung adenocarcinoma. Ann Med. 2023;55:2241013. https://doi.org/10.1080/07853890.2023.2241013.CrossRefPubMedPubMedCentral

207.

Li J, Wang J, Chen Z, Hu P, Zhang X, Guo X, et al. In: Huang Y, editor. An exosome-related long non-coding RNA (lncRNA)-Based signature for prognosis and therapeutic interventions in Lung Adenocarcinoma. Volume 15. Cureus; 2023. p. e47574. https://doi.org/10.7759/cureus.47574.

208.

Chen Z, Wei J, Li M, Zhao Y. A circular RNAs dataset landscape reveals potential signatures for the detection and prognosis of early-stage lung adenocarcinoma. BMC Cancer. 2021;21:781. https://doi.org/10.1186/s12885-021-08293-7.CrossRefPubMedPubMedCentral

209.

Jiang X, Gao YL, Li JY, Tong YY, Meng ZY, Yang SG, Zhu CT. An anoikis-related lncRNA signature is a useful tool for predicting the prognosis of patients with lung adenocarcinoma. Heliyon. 2023;9:e22200. https://doi.org/10.1016/j.heliyon.2023.e22200.CrossRefPubMedPubMedCentral

210.

Jin S, Liu T, Wang W, Li T, Liu Z, Zhang M. Lymphocyte migration regulation related proteins in urine exosomes may serve as a potential biomarker for lung cancer diagnosis. BMC Cancer. 2023;23:1125. https://doi.org/10.1186/s12885-023-11567-x.CrossRefPubMedPubMedCentral

211.

Jing H, Meng M, Ye M, Liu S, Cao X, Li K, Wu Y, et al. Integrin α2 promotes immune escape in non-small cell lung cancer by enhancing PD-L1 expression in exosomes to inhibit CD8 + T cell activity. J Invest Medicine: Official Publication Am Federation Clin Res. 2023;10815589231207801. https://doi.org/10.1177/10815589231207801.

212.

Cui Q, Li W, Wang D, Wang S, Yu J. Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis. World J Surg Oncol. 2023;21:318. https://doi.org/10.1186/s12957-023-03215-2.CrossRefPubMedPubMedCentral

213.

Murakami D, Matsuda K, Iwamoto H, Mitani Y, Mizumoto Y, Nakamura Y, Yamaue H, et al. Prognostic value of CD155/TIGIT expression in patients with colorectal cancer. PLoS ONE. 2022;17:e0265908. https://doi.org/10.1371/journal.pone.0265908.CrossRefPubMedPubMedCentral

214.

Wang D, Gu Y, Yan X, Huo C, Wang G, Zhao Y, Li Y, et al. Role of CD155/TIGIT in Digestive cancers: Promising Cancer Target for Immunotherapy. Front Oncol. 2022;12:844260. https://doi.org/10.3389/fonc.2022.844260.CrossRefPubMedPubMedCentral

215.

Wang N, Chai M, Zhu L, Liu J, Yu C, Huang X. Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma. Front Immunol. 2023;14:1070953. https://doi.org/10.3389/fimmu.2023.1070953.CrossRefPubMedPubMedCentral

216.

Zhang P, Pei S, Wu L, Xia Z, Wang Q, Huang X, Lin H, et al. Integrating multiple machine learning methods to construct glutamine metabolism-related signatures in lung adenocarcinoma. Front Endocrinol. 2023;14:1196372. https://doi.org/10.3389/fendo.2023.1196372.CrossRef

217.

Wang H, Wang X, Xu L, Zhang J, Cao H. High expression levels of pyrimidine metabolic rate-limiting enzymes are adverse prognostic factors in lung adenocarcinoma: a study based on the Cancer Genome Atlas and Gene expression Omnibus datasets, Purinergic signalling, 16 (2020) 347–66https://doi.org/10.1007/s11302-020-09711-4.

218.

Wu J, Hu S, Zhang L, Xin J, Sun C, Wang L, Wang B, et al. Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis. Theranostics. 2020;10:4544–56. https://doi.org/10.7150/thno.40532.CrossRefPubMedPubMedCentral

219.

Ge X, Yuan L, Cheng B, Dai K. Identification of seven tumor-educated platelets RNAs for cancer diagnosis. J Clin Lab Anal. 2021;35:e23791. https://doi.org/10.1002/jcla.23791.CrossRefPubMedPubMedCentral

220.

Li X, Liu L, Song X, Wang K, Niu L, Xie L, Song X. TEP linc-GTF2H2-1, RP3-466P17.2, and lnc-ST8SIA4-12 as novel biomarkers for lung cancer diagnosis and progression prediction. J Cancer Res Clin Oncol. 2021;147:1609–22. https://doi.org/10.1007/s00432-020-03502-5.CrossRefPubMed

221.

Kao YR, Roffler W-C et al. Tumor-associated antigen L6 and the invasion of human lung cancer cells.

222.

Moran JA-O, Adams DA-O, Edelman MA-O, Lopez PA-O, He J, Qiao Y et al. Lin SA-O, Monitoring PD-L1 expression on circulating Tumor-Associated cells in recurrent metastatic non-small-cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy.

223.

Mizukami M, Hanagiri T, Fau - T, Baba T, Baba T, Fau - Fukuyama Y, Fukuyama T, Fau - Nagata T, Nagata Y, Fau - So Y, So T, Fau, Ichiki et al. Yasumoto K, Identification of tumor associated antigens recognized by IgG from tumor-infiltrating B cells of lung cancer: correlation between Ab titer of the patient’s sera and the clinical course.

224.

Tamminga MA-O, de Wit S, Hiltermann TJN, Timens W, Schuuring E, Terstappen L, Groen HJM. Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors.

225.

Castello AA-O, Carbone FG, Rossi S, Monterisi S, Federico D, Toschi L. E.A.-O. Lopci, circulating Tumor cells and metabolic parameters in NSCLC patients treated with checkpoint inhibitors. LID – 10.3390/cancers12020487 [doi] LID – 487,.

226.

Guibert N, Delaunay M, Lusque A, Boubekeur N, Rouquette I, Clermont E, Pradines A et al. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.

227.

Janning MA-O, Kobus F, Babayan A, Wikman HA-O, Velthaus JL, Bergmann S, S., Loges et al. Determination of PD-L1 expression in circulating Tumor cells of NSCLC patients and correlation with response to PD-1/PD-L1 inhibitors. LID – 10.3390/cancers11060835 [doi] LID – 835,.

228.

Ilié M, Szafer-Glusman E, Hofman V, Chamorey E, Lalvée S, Selva E, Hofman P et al. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.

229.

Passiglia F, Galvano A, Castiglia M, Incorvaia L, Calò V, Listì A et al. A.A.-O. Russo, monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients.

230.

Anagnostou V, Forde PM, White JR, Niknafs NA-O, Hruban CA-OX, Naidoo J et al. V.A.-O.X. Velculescu, Dynamics of Tumor and Immune responses during Immune Checkpoint Blockade in Non-small Cell Lung Cancer.

231.

Moding EA-O, Liu Y, Nabet BA-O, Chabon JJ, Chaudhuri AA-O, Hui AB et al. M.A.-O. Diehn, circulating Tumor DNA Dynamics Predict Benefit from consolidation immunotherapy in locally Advanced Non-Small Cell Lung Cancer.

232.

Skoulidis F, Goldberg MA-O, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF et al. J.A.-O. Heymach, STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-Mutant Lung Adenocarcinoma.

233.

Del Re M, Marconcini R, Pasquini G, Rofi E, Vivaldi C, Bloise F, Danesi R et al. PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC.

234.

Yang Q, Chen M, Gu J, Niu K, Zhao X, Zheng L et al. J. Sun, Novel biomarkers of dynamic blood PD-L1 expression for Immune checkpoint inhibitors in Advanced Non-Small-Cell Lung Cancer Patients.

235.

Peng XX, Yu R, Wu X, Wu SY, Pi C, Chen ZH et al. Q.A.-O.X. Zhou, correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer. LID – 10.1136/jitc-2019-000376 [doi] LID - e000376,.

236.

Fan J, Yin Z, Xu J, Wu F, Huang Q, Yang L, Yang G et al. Circulating microRNAs predict the response to anti-PD-1 therapy in non-small cell lung cancer.

237.

Boeri MA-O, Milione M, Proto C, Signorelli D, Lo Russo GA-O, Galeone C et al. G. Sozzi, circulating miRNAs and PD-L1 tumor expression are Associated with Survival in Advanced NSCLC patients treated with immunotherapy: a prospective study.

238.

Fahrmann JF, Saini NY, Chia-Chi C, Irajizad E, Strati P, Nair R, Hanash S et al. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma.

239.

Grobben Y, den Ouden JE, Aguado C, van Altena AM, Kraneveld AA-OX, Zaman GJR. Amino acid-metabolizing enzymes in Advanced High-Grade Serous Ovarian Cancer patients: Value of ascites as Biomarker source and role for IL4I1 and IDO1. LID – 10.3390/cancers15030893 [doi] LID – 893,.

240.

Rolfes V, Idel C, Pries R, Plötze-Martin K, Habermann J, Gemoll T, Wollenberg B et al. PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.

241.

Kraemer AI, Chong C, Huber FA-O, Pak H, Stevenson BJ, Müller M et al. M.A.-O.X. Bassani-Sternberg, the immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer.

242.

Hu F, Huang D, Luo Y, Zhou P, Lv C, Wang K et al. H.A.-O.X. Wu, hematopoietic lineage-converted T cells carrying tumor-associated antigen-recognizing TCRs effectively kill tumor cells. LID – 10.1136/jitc-2019-000498 [doi] LID - e000498,.

243.

Qi J, Li M, Wang L, Hu Y, Liu W, Long Z, Zhou M, et al. National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data, the Lancet. Public Health. 2023;8:e943–55. https://doi.org/10.1016/s2468-2667(23)00211-6.

244.

Plava J, Cihova M, Burikova M, Bohac M, Adamkov M, Drahosova S et al. S. Miklikova, Permanent Pro-tumorigenic Shift in Adipose tissue-derived mesenchymal stromal cells Induced by breast malignancy, cells, 9 (2020).https://doi.org/10.3390/cells9020480.

245.

Liu X, Wang C, Zhang L, Gu H, Yang J, Wang Y, Tan J. Prognostic and Diagnostic Values of Circulating Tumor Cells and tumor markers for Lung Cancer, Clinical laboratory, 67 (2021).https://doi.org/10.7754/Clin.Lab.2020.200654.

246.

Chen X, Wang X, He H, Liu Z, Hu JF, Li W. Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer. PLoS ONE. 2015;10:e0126276. https://doi.org/10.1371/journal.pone.0126276.CrossRefPubMedPubMedCentral

247.

Wang W, Zhang T. Expression and analysis of PD-L1 in peripheral blood circulating tumor cells of lung cancer. Future Oncol (London England). 2021;17:1625–35. https://doi.org/10.2217/fon-2020-0683.CrossRef

248.

Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, Velculescu VE, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017;9. https://doi.org/10.1126/scitranslmed.aan2415.

249.

Leung M, Freidin MB, Freydina DV, Von Crease C, De Sousa P, Barbosa MT, Lim E, et al. Blood-based circulating tumor DNA mutations as a diagnostic and prognostic biomarker for lung cancer. Cancer. 2020;126:1804–9. https://doi.org/10.1002/cncr.32699.CrossRefPubMed

250.

Zhu HZ, Fang CJ, Guo Y, Zhang Q, Huang LM, Qiu D, Chen ZT, et al. Detection of mir-155-5p and imaging lung cancer for early diagnosis: in vitro and in vivo study. J Cancer Res Clin Oncol. 2020;146:1941–51. https://doi.org/10.1007/s00432-020-03246-2.CrossRefPubMedPubMedCentral

251.

Wang J, Zhang L, Wang C, Chen Y, Sui X. LINC00313/miR-4429 axis provides novel biomarkers for the diagnosis and prognosis of non-small cell lung cancer. Acta Biochim Pol. 2022;69:343–8. https://doi.org/10.18388/abp.2020_5794.CrossRefPubMed

252.

Zhao YL, Zhang JX, Yang JJ, Wei YB, Peng JF, Fu CJ, Xie SY, et al. MiR-205-5p promotes lung cancer progression and is valuable for the diagnosis of lung cancer. Thorac cancer. 2022;13:832–43. https://doi.org/10.1111/1759-7714.14331.CrossRefPubMedPubMedCentral

253.

Gao Z, Yuan H, Mao Y, Ding L, Effah CY, He S, Wu Y et al. In situ detection of plasma exosomal microRNA for lung cancer diagnosis using duplex-specific nuclease and MoS(2) nanosheets, the analyst, 146 (2021) 1924–31https://doi.org/10.1039/d0an02193h.

254.

Chen J, Xu Y, Wang X, Liu D, Yang F, Zhu X, Xing W et al. Rapid and efficient isolation and detection of extracellular vesicles from plasma for lung cancer diagnosis, lab on a chip, 19 (2019) 432–43https://doi.org/10.1039/c8lc01193a.

255.

Xiao S, Yao Y, Liao S, Xu B, Li X, Zhang Y, Dong M et al. Accurate and convenient Lung Cancer diagnosis through detection of Extracellular Vesicle membrane proteins via Förster Resonance Energy Transfer, Nano letters, 23 (2023) 8115–25https://doi.org/10.1021/acs.nanolett.3c02193.

256.

Takamori S, Ishikawa S, Suzuki J, Oizumi H, Uchida T, Ueda S, Sugimoto M et al. Differential diagnosis of lung cancer and benign lung lesion using salivary metabolites: a preliminary study, thoracic cancer, 13 (2022) 460–5https://doi.org/10.1111/1759-7714.14282.

257.

Esposito A, Criscitiello C, Trapani D, Curigliano G. The emerging role of Liquid biopsies, circulating Tumor cells, and circulating cell-free tumor DNA in Lung Cancer diagnosis and identification of resistance mutations. Curr Oncol Rep. 2017;19:1. https://doi.org/10.1007/s11912-017-0564-y.CrossRefPubMed

258.

Spiliotaki M, Neophytou CM, Vogazianos P, Stylianou I, Gregoriou G, Constantinou AI, Charalambous H, et al. Dynamic monitoring of PD-L1 and Ki67 in circulating tumor cells of metastatic non-small cell lung cancer patients treated with pembrolizumab. Mol Oncol. 2023;17:792–809. https://doi.org/10.1002/1878-0261.13317.CrossRefPubMed

259.

Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, Diehn M et al. Early detection of molecular residual disease in localized Lung Cancer by circulating Tumor DNA profiling, Cancer discovery, 7 (2017) 1394–403https://doi.org/10.1158/2159-8290.Cd-17-0716.

260.

Waldeck S, Mitschke J, Wiesemann S, Rassner M, Andrieux G, Deuter M, et al. N. Von Bubnoff, early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer. Mol Oncol. 2022;16:527–37. https://doi.org/10.1002/1878-0261.13116.CrossRefPubMed

261.

Wang S, Li M, Zhang J, Xing P, Wu M, Meng F, Yin R, et al. Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer. J Hematol Oncol. 2022;15:137. https://doi.org/10.1186/s13045-022-01355-8.CrossRefPubMedPubMedCentral

262.

Chen K, Yang F, Shen H, Wang C, Li X, Chervova O, Wang J, et al. Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer. Cancer Cell. 2023;41:1749–62. https://doi.org/10.1016/j.ccell.2023.08.010.CrossRefPubMed

263.

Pandey M, Mukhopadhyay A, Sharawat SK, Kumar S. Role of microRNAs in regulating cell proliferation, metastasis and chemoresistance and their applications as cancer biomarkers in small cell lung cancer, Biochimica et biophysica acta. Reviews cancer. 2021;1876:188552. https://doi.org/10.1016/j.bbcan.2021.188552.CrossRef

264.

Jin M, Zhang F, Li Q, Xu R, Liu Y, Zhang Y. Circ_0011292 knockdown mitigates progression and drug resistance in PTX-resistant non-small-cell lung cancer cells by regulating miR-433-3p/CHEK1 axis, thoracic cancer, 13 (2022) 1276–88https://doi.org/10.1111/1759-7714.14378.

265.

de Miguel-Perez D, Ortega FG, Tejada RG, Martínez-Única A, Peterson CB, Russo A, Serrano MJ, et al. Baseline extracellular vesicle miRNA-30c and autophagic CTCs predict chemoradiotherapy resistance and outcomes in patients with lung cancer. Biomark Res. 2023;11:98. https://doi.org/10.1186/s40364-023-00544-y.CrossRefPubMedPubMedCentral

266.

Zhang Y, Chao F, Lv L, Li M, Shen Z. Hsa_circ_0041150 serves as a novel biomarker for monitoring chemotherapy resistance in small cell lung cancer patients treated with a first-line chemotherapy regimen. J Cancer Res Clin Oncol. 2023;149:15365–82. https://doi.org/10.1007/s00432-023-05317-6.CrossRefPubMedPubMedCentral

267.

Takahashi T, Fujiwara Y, Sumiyoshi H, Isobe T, Yamaoka N, Yamakido M. Salivary drug monitoring of irinotecan and its active metabolite in cancer patients. Cancer Chemother Pharmacol. 1997;40:449–52. https://doi.org/10.1007/s002800050685.CrossRefPubMed

268.

Miller HA, Yin X, Smith SA, Hu X, Zhang X, Yan J, Frieboes HB et al. Evaluation of disease staging and chemotherapeutic response in non-small cell lung cancer from patient tumor-derived metabolomic data, lung cancer (Amsterdam, Netherlands), 156 (2021) 20–30https://doi.org/10.1016/j.lungcan.2021.04.012.

269.

Rolfes V, Idel C, Pries R, Plötze-Martin K, Habermann J, Gemoll T, Wollenberg B, et al. PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy. Oncotarget. 2018;9:27460–70. https://doi.org/10.18632/oncotarget.25446.CrossRefPubMedPubMedCentral

270.

Jin F, Zhu L, Shao J, Yakoub M, Schmitt L, Reißfelder C, S., Schölch, et al. Circulating tumour cells in patients with lung cancer universally indicate poor prognosis. Eur Respiratory Review: Official J Eur Respiratory Soc. 2022;31. https://doi.org/10.1183/16000617.0151-2022.

271.

Abbosh C, Frankell AM, Harrison T, Kisistok J, Garnett A, Johnson L, Swanton C, et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature. 2023;616:553–62. https://doi.org/10.1038/s41586-023-05776-4.CrossRefPubMedPubMedCentral

272.

Yin JX, Hu WW, Gu H, Fang JM. Combined assay of circulating Tumor DNA and protein biomarkers for early noninvasive detection and prognosis of Non-small Cell Lung Cancer. J Cancer. 2021;12:1258–69. https://doi.org/10.7150/jca.49647.CrossRefPubMedPubMedCentral

273.

Zhang H, Liu M, Du G, Yu B, Ma X, Gui Y, Tan B, et al. Immune checkpoints related-LncRNAs can identify different subtypes of lung cancer and predict immunotherapy and prognosis. J Cancer Res Clin Oncol. 2022;148:1597–612. https://doi.org/10.1007/s00432-022-03940-3.CrossRefPubMed

274.

Wang LF, Wu LP, Wen JD. LncRNA AC079630.4 expression associated with the progression and prognosis in lung cancer. Aging. 2021;13:18658–68. https://doi.org/10.18632/aging.203310.CrossRefPubMedPubMedCentral

275.

Li C, Wang W, Sun Y, Ni Y, Qin F, Li X, Sun G, et al. Selective sorting and secretion of hY4 RNA fragments into extracellular vesicles mediated by methylated YBX1 to promote lung cancer progression. J Experimental Clin cancer Research: CR. 2022;41:136. https://doi.org/10.1186/s13046-022-02346-w.CrossRefPubMedCentral

276.

Pontis F, Roz L, Mensah M, Segale M, Moro M, Bertolini G, et al. In: Sozzi G, editor. Circulating extracellular vesicles from individuals at high-risk of lung cancer induce pro-tumorigenic conversion of stromal cells through transfer of miR-126 and miR-320. Journal of experimental & clinical cancer research. Volume 40. CR; 2021. p. 237. https://doi.org/10.1186/s13046-021-02040-3.

277.

Patel DP, Pauly GT, Tada T, Parker AL, Toulabi L, Kanke Y, Harris CC, et al. Improved detection and precise relative quantification of the urinary cancer metabolite biomarkers - Creatine Riboside, creatinine riboside, creatine and creatinine by UPLC-ESI-MS/MS: application to the NCI-Maryland cohort population controls and lung cancer cases. J Pharm Biomed Anal. 2020;191:113596. https://doi.org/10.1016/j.jpba.2020.113596.CrossRefPubMedPubMedCentral

278.

Parker AL, Toulabi L, Oike T, Kanke Y, Patel D, Tada T, Harris CC, et al. Creatine Riboside is a cancer cell-derived metabolite associated with arginine auxotrophy. J Clin Investig. 2022;132. https://doi.org/10.1172/jci157410.

279.

Omar M, Tanriverdi O, Cokmert S, Oktay E, Yersal O, Pilancı KN, Barutca S et al. Role of increased mean platelet volume (MPV) and decreased MPV/platelet count ratio as poor prognostic factors in lung cancer, the clinical respiratory journal, 12 (2018) 922–9https://doi.org/10.1111/crj.12605.

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation

Abstract

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Transcriptional regulation of cancer stem cell: regulatory factors elucidation and cancer treatment strategies

Natural killer cells drive 4-1BBL positive uveal melanoma towards EMT and metastatic disease

Augmented ERO1α upon mTORC1 activation induces ferroptosis resistance and tumor progression via upregulation of SLC7A11

LINC00571 drives tricarboxylic acid cycle metabolism in triple-negative breast cancer through HNRNPK/ILF2/IDH2 axis

A phenotypic screening approach to target p60AmotL2-expressing invasive cancer cells

CircCDYL2 bolsters radiotherapy resistance in nasopharyngeal carcinoma by promoting RAD51 translation initiation for enhanced homologous recombination repair

Keynote webinar | Spotlight on antibody–drug conjugates in cancer